✓After hours - Last update: Oct 14, 2026, 10:08 AM ET
⚠️Material / Earnings✓High confidence
Source: earnings_events
Changes History →Market closed · After hours · 5:56 PM ET
Last update: Oct 14, 2026, 5:18 PM ETMarket closed·100 changes confirmed today
Track the stock moves that actually matter.
BestStocks detects meaningful changes across price, volume, earnings, filings, valuation, analyst revisions, and risk signals — and shows you the evidence behind each one.
1,000 equities monitored14 signal typesCross-checked against SEC EDGARMedian detection lag ~41s
Investment research built around change detection.
Showing:
BestStocks identifies what changed across companies and sectors, explains why it matters, and helps investors spot opportunities worth investigating.
✓After hours - Last update: Oct 14, 2026, 4:39 PM ET
🛡Material / Earnings✓High confidence
What changed: Core Scientific, Inc. (CORZ) moved -9.15% from $14.87 to $13.51 on 2026-10-14, reaching a new 30-day low on volume 2.6x the 5-day average. We checked news, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found.
Source: daily_prices:fmp_change_percent
Changes History →What's next
What to watch
Monitor the 2026-10-23 earnings announcement for any guidance or operational updates that could explain the recent weakness.
✓After hours - Last update: Oct 14, 2026, 4:38 PM ET
⚡Material / Earnings✓High confidence
What changed: Fastenal Company (FAST) moved +9.45% from $47.51 to $52.00 on 2026-10-14 after reporting Q3 EPS of $0.35, beating consensus by $0.01 (+3.28% surprise). Revenue came in at $2.463B versus $2.440B estimate, with EPS growing 21% year-over-year driven by increased customer spending.
Source: daily_prices:fmp_change_percent
Changes History →What's next
What to watch
Next earnings scheduled for 2027-01-19 with consensus EPS estimate of $0.31.
✓After hours - Last update: Oct 14, 2026, 10:08 AM ET
🏆Material / Earnings✓High confidence
What changed: BlackRock, Inc. (BLK) reported EPS of $15.93 vs. consensus estimate of $14.32, beating by 11.2% on 2026-10-14.
Source: earnings_events
Changes History →What's next
What to watch
BLK is scheduled to report earnings on 2027-01-21 against a consensus EPS estimate of $15.12.
✓After hours - Last update: Oct 14, 2026, 4:44 PM ET
🛡Material / Earnings✓High confidence
What changed: Rigetti Computing, Inc. (RGTI) moved -5.36% from $12.34 to $11.68 on 2026-10-14, reaching a new 30-day low on modestly elevated volume (1.8x the 5-day average). News from earlier in the period highlighted RGTI's $100M government R&D funding and $8.4M commercial order from C-DAC, signaling a transition from development to operational validation, yet the stock has trended lower and is trading at a 49% premium to its GF Value estimate of $8.92.
Source: daily_prices:fmp_change_percent
Changes History →What's next
What to watch
Q3 earnings results on 2026-11-09 and management commentary on C-DAC order execution and government funding deployment timelines.
✓After hours - Last update: Oct 14, 2026, 4:44 PM ET
🛡Material / Earnings✓High confidence
What changed: Fervo Energy Co. (FRVO) moved -7.29% from $11.80 to $10.94 on 2026-10-14, reaching a new 30-day low. The decline follows a Morpheus Research short report alleging severe structural and operational issues at Fervo's Cape Station project in Utah—including thermal decline, excessive water loss, and seismicity-related equipment damage—and multiple securities class action investigations by Rosen Law Firm and Kirby McInerney alleging potential misleading statements to shareholders. The stock has retreated 60% from its May 2026 IPO price of $27 per share.
Source: daily_prices:fmp_change_percent
Changes History →What's next
What to watch
Fervo Energy earnings on 2026-11-11 (consensus EPS estimate: -$0.09).
✓After hours - Last update: Oct 14, 2026, 4:39 PM ET
🛡Material / Earnings✓High confidence
What changed: Vishay Intertechnology, Inc. (VSH) moved -6.05% from $30.75 to $28.89 on 2026-10-14, reaching a new 30-day low. We checked news, earnings, analyst updates, filings, and corporate actions — no company-specific catalyst was found. The company announced automotive-grade optical sensors with photodiode output supporting 6 Mbit/s data rates and 9 ns response times, but this announcement does not appear to have triggered the move.
Source: daily_prices:fmp_change_percent
Changes History →What's next
What to watch
Vishay earnings on 2026-11-04 to assess whether the recent decline reflects expectations being reset or earnings risk.
✓After hours - Last update: Oct 14, 2026, 4:39 PM ET
🛡Material / Earnings✓High confidence
What changed: Galaxy Digital (GLXY) moved -5.73% from $19.02 to $17.93 on October 14, 2026, to a new 30-day low on modestly elevated volume (1.8x average). The decline came despite a Citigroup upgrade to Buy with a $28 price target, as analysts project the company will miss Q3 2026 earnings expectations due to unfavorable fundamental conditions.
Source: daily_prices:fmp_change_percent
Changes History →What's next
What to watch
Galaxy Digital's Q3 2026 earnings release on October 27, 2026—actual results versus the consensus EPS estimate of -$0.01 and guidance commentary.
✓After hours - Last update: Oct 14, 2026, 4:39 PM ET
⚡Material / Earnings✓High confidence
What changed: Halozyme Therapeutics, Inc. (HALO) moved +6.35% from $109.84 to $116.82 on 2026-10-14, reaching a new 30-day high on volume 1.9x the 5-day average. No company-specific news, earnings announcement, or corporate action was found on or immediately before the move date.
Source: daily_prices:fmp_change_percent
Changes History →What's next
What to watch
HALO earnings announcement on 2026-11-02 (date not yet confirmed) and the actual EPS result versus the $2.28 consensus estimate.
✓After hours - Last update: Oct 14, 2026, 4:39 PM ET
⚡Material / Earnings✓High confidence
What changed: Chewy, Inc. (CHWY) moved +5.63% from $19.72 to $20.83 on 2026-10-14. We checked news, earnings, analyst updates, filings, and corporate actions — no company-specific catalyst was found. Volume was near its 5-day average.
Source: daily_prices:fmp_change_percent
Changes History →What's next
What to watch
Chewy earnings report due 2026-12-09 with consensus EPS estimate of $0.38.
✓After hours - Last update: Oct 14, 2026, 4:39 PM ET
⚡Material / Earnings✓High confidence
What changed: Etsy, Inc. (ETSY) moved +5.12% from $78.89 to $82.93 on October 14, 2026, extending a seven-day winning streak. The company announced it will release Q3 2026 earnings on October 28, 2026 before market open. Recent catalysts supporting sentiment include rollout of AI-driven search and personalization features, workforce streamlining, and renewal of its international payments partnership with Payoneer through 2029.
Source: daily_prices:fmp_change_percent
Changes History →What's next
What to watch
Etsy's Q3 2026 earnings release on October 28, 2026 before market open, with consensus EPS estimate of $0.76.
✓After hours - Last update: Oct 14, 2026, 4:39 PM ET
🛡Material / Earnings✓High confidence
What changed: Joby Aviation, Inc. (JOBY) moved -6.40% from $4.92 to $4.61 on 2026-10-14, reaching a new 30-day low. The decline extends a broader downward slide following a federal jury verdict on October 9 ordering Joby to pay $116.9 million in damages to supplier Aerosonic in a trade-secrets lawsuit, which triggered an 8% drop that day. Volume remained near its 5-day average.
Source: daily_prices:fmp_change_percent
Changes History →What's next
What to watch
Joby Aviation earnings are scheduled for 2026-11-04, with consensus EPS estimate of −$0.25.
Latest research
View all research →In-depth equity research from the BestStocks desk — earnings breakdowns, valuation deep dives, and sector analysis behind the changes we detect.
Stock AnalysisOctober 13, 2026 · 10 min read
Johnson & Johnson (JNJ) Falls ~6% Despite a Q3 Beat-and-Raise
Johnson & Johnson fell about 6% to roughly $247.63 on October 13 after third-quarter results — an unusually large move for a defensive Dow stalwart with a beta near 0.21. The strange part: at the headline it was a beat-and-raise. Adjusted earnings of $2.59 topped estimates and the company raised full-year guidance, lifting adjusted EPS to about $11.10 at the midpoint and putting sales on track to cross $100 billion for the first time. The stock fell anyway, and the main reason was the device business: MedTech sales of about $8.6 billion grew just 2.5% and missed Wall Street's estimate for a second straight quarter, against a strong 7.9% for the Innovative Medicine drug division. On top of that, the guidance raise was modest, the adjusted 'beat' was still down about 7.5% from a year earlier, and the stock had run up about 30% over the past year, leaving it priced for good news. A separate, largely accounting story grabbed headlines: reported GAAP net income collapsed to about $210 million (EPS of $0.09) on roughly $7.6 billion of special charges, about $5.5 billion of it a talc-litigation provision — but that settlement had been announced back in July, so the quarter merely booked the charge rather than breaking news. Pharma peers and the market barely moved, confirming a company-specific drop. The trailing P/E near 30 looks alarming but is distorted by the charges; on adjusted earnings the stock trades closer to 22 times forward. Analysts keep a Buy consensus with an average target near $280, above the price.
JNJRead →
Stock AnalysisOctober 12, 2026 · 10 min read
IonQ (IONQ) Falls ~9% on a $1.3B All-Stock Cybersecurity Acquisition
IonQ fell about 9% to roughly $36 on October 12 on a day it announced a definitive agreement to acquire Elisity, a zero-trust cybersecurity company, in an all-stock deal worth up to $1.3 billion. The counterintuitive part is the point: a stock dropping on its own acquisition. The all-stock structure is why — IonQ's share count is already up about 50% over the past year as it funds an acquisition-and-fundraising spree largely with stock, and Elisity is its third billion-dollar-scale deal in roughly 16 months, after the mostly-stock Oxford Ionics purchase and the cash-and-stock SkyWater acquisition. The strategic logic is forward-looking (pairing post-quantum cryptography with Elisity's zero-trust platform to sell 'quantum-era' security), but the market read the news as more dilution and more strategic sprawl from a pre-profit company valued near $14 billion on just $246 million of revenue — about 58 times sales, with an operating margin near negative 380%. A sign of company-specific pressure: IonQ fell about 9% while quantum peers Rigetti and D-Wave fell closer to 5.5% and the Nasdaq-100 slipped under 1% — more than the sector alone would explain. Wall Street stays overwhelmingly bullish on the long-term quantum roadmap — a Strong Buy consensus with an average target far above the price — which is exactly why a story stock like this swings so violently on news.
IONQRead →
Stock AnalysisOctober 12, 2026 · 10 min read
Manhattan Associates (MANH) Jumps ~6% on a Morgan Stanley Upgrade to Overweight
Manhattan Associates jumped about 5.5% to roughly $216 on October 12 — after running as high as about $221 — on a Morgan Stanley upgrade to Overweight from Equalweight and a price-target raise to $250 from $180. The move bucked a down software tape: supply-chain peers were flat and the software sector fell, marking this as an idiosyncratic, catalyst-driven move. Analyst Chris Quintero leaned on three points — accelerating cloud subscription bookings under CEO Eric Clark, a narrative shift from Manhattan being seen as AI-vulnerable to an AI beneficiary via its agentic-AI suite, and a more attractive valuation — while citing only about 1–2% upside to consensus revenue, a tell that this is a re-rating of sentiment as much as of the numbers. The business is a genuinely profitable, cash-generative franchise (56% gross margins, ~25% operating margins, a net-cash balance sheet, ~$400M of free cash flow, cloud revenue up in the mid-20s percent), but it is not cheap: near a 52-week high at ~62x trailing and ~37x forward earnings after a ~70% six-month run, the upgrade pushed it to within a few percent of the ~$228 average analyst target. The next hard test is third-quarter earnings on October 27.
MANHRead →
Stock AnalysisOctober 8, 2026 · 9 min read
Chipotle (CMG) Surges ~6% on a Report Starbucks Explored a Takeover
Chipotle jumped about 6% to roughly $32.54 on October 8 — after running as high as about $33.40 — on a Financial Times report that Starbucks has explored a potential takeover of the burrito chain. The key word is explored: the report describes preliminary, exploratory interest, not a formal offer, and neither company confirmed a deal, so this is a stock moving on takeover speculation that could reverse if the idea goes no further. The speculation still landed hard — volume ran about three times normal — because a Starbucks–Chipotle combination would be enormous (nearly $50 billion in combined sales, potentially the largest restaurant deal ever if completed) and would reunite Starbucks CEO Brian Niccol with the chain he ran from 2018 to 2024. It resonated partly because Chipotle had become cheap for Chipotle: down about 19% over the past year and trading below the ~$44 average analyst target even after the pop, a high-quality, cash-generative brand at a discount is exactly the profile that draws suitors. But skepticism is warranted: Starbucks fell about 3% on the prospect of a $45-billion-plus deal that would strain its balance sheet mid-turnaround, the strategic fit between coffee and fast-casual Mexican is debatable, and exploratory interest frequently never becomes an offer. The classic M&A-speculation cross-section — target up, acquirer down, McDonald's higher — tells the story; the next hard data is Chipotle's October 28 earnings.
CMGRead →
Stock AnalysisOctober 7, 2026 · 10 min read
NetApp (NTAP) Rises ~3.5% as Evercore Upgrades to a Street-High $300 on AI Storage
NetApp outperformed a weaker broader market on October 7, rising about 3.5% to roughly $236.50 after Evercore ISI's Amit Daryanani upgraded the stock from In Line to Outperform and set a Street-high $300 price target, up from $210. The move was less about one call than the cluster behind it: over roughly a week, Loop Capital went to $260, TD Cowen to $250, and Goldman to $240, and Evercore has now leapfrogged them all with a rating upgrade — a sell-side re-rating of NetApp as an AI-storage beneficiary, its all-flash arrays and ONTAP software positioned for the data pipelines that feed GPU clusters (a story reinforced by its late-September deal to buy PEAK:AIO and its Novus launch, both earlier developments rather than a fresh catalyst). NetApp rose even as long-dated Treasury yields hit their highest since 2002 in a rates- and oil-driven risk-off that pressured high-multiple shares. But the stock is not cheap: up roughly 96% over the past year, it trades near 23 times forward earnings and 6 times sales for a business growing revenue in the low-double-digits, so the upgrades are betting AI lifts both growth and the multiple. And the Street is genuinely split — the published average target near $206 sits below the price, reflecting both the lag before the newest hikes propagate and real disagreement: a camp of fresh below-price targets (Wedbush's Hold at $170, plus Citi, Barclays and Bank of America in the $190–$220 range) against the bulls at $240–$300. Without an unusually heavy-volume surge, this is a sell-side re-rating; the fundamentals arrive with December 1 earnings.
NTAPRead →
Stock AnalysisOctober 5, 2026 · 9 min read
Vaxcyte (PCVX) Surges ~35% as VAX-31 Meets All Primary Endpoints in Pivotal Phase 3 Trial
Vaxcyte surged to roughly $76 on October 5 — up about 35% after opening near $87 (about +54%) — when it reported positive topline data from OPUS-1, the pivotal adult Phase 3 trial of VAX-31, its 31-valent pneumococcal conjugate vaccine. The trial met all of its prespecified primary endpoints on immune-response and safety measures: in adults 50 and older, VAX-31 met non-inferiority on all 20 serotypes it shares with Pfizer's Prevnar 20 and 17 of the 19 it shares with Merck's Capvaxive (the two exceptions cleared only a less-stringent historical bar), and superiority on the three serotypes unique to VAX-31, with safety similar to the incumbents. It is the profile a broader, 31-valent shot needs to take share in a multi-billion-dollar adult pneumococcal market — and the market priced it as a transfer of value, with Pfizer down about 1.6% and Merck about 3.4% while the biotech index was flat. Vaxcyte is still a clinical-stage, pre-revenue company — a roughly $1 billion annual loss, no P/E, and years from revenue, with two more Phase 3 trials due in 2027 and a planned filing in 2028 — but about $2.5 billion of cash and investments gives it runway, and sell-side targets sit well above the current price (Guggenheim raised its target to $125 the same day; Mizuho and Jefferies reiterated standing Buys at $163 and $146). The stock's gap-up-then-fade captures the tension between clearly good data and the execution still ahead.
PCVXRead →